Navigation Links
Pixantrone Shows Activity in a Preclinical Study of Experimental Autoimmune Myasthenia Gravis (EAMG)
Date:2/11/2008

ve clinically in a number of tumor types. However, they are usually associated with cumulative heart damage that prevents them from being used in a large proportion of patients. Pixantrone has been designed to reduce the potential for these severe cardiotoxicities, as well as to potentially increase activity and permit simplified administration compared to the currently marketed anthracyclines.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit http://www.cticseattle.com.

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties that could affect the development of pixantrone include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and with pixantrone in particular including, without limitation, the potential failure of pixantrone to be tested in or have comparable results in human clinical trials of myasthenia gravis, determinations by regulatory, patent and administrative governmental authorities, competitive factors, technological developments, costs of developing, producing and selling pixantrone, and the risk factors listed or described from time to time in the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's most recent filings on Forms 10-K, 8-K, and 10-Q. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.

Media Contact:

Dan Eramian

T: 206.272.4343

C: 206.854.12
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pixantrone Versus Doxorubicin in CHOP-R Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Preliminary Results Presented at American Society of Hematology (ASH) Annual Meeting
2. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
3. Novel Small Molecule Therapy Shows Benefit for Anemic Patients Via Hydration of Red Blood Cells
4. JAK2 Inhibitor Shows Potent Activity in Cells From MPD Patients
5. Newly Approved HIV Drug Shows Great Promise
6. Kaiser Permanente - Group Health Study Shows Depression Worsens HIV Treatment
7. Research Shows Decas Sweetened Dried Cranberries Pack Twice the Proanthocyanidin Punch as Cranberry Juice Cocktail
8. New Study Shows LEVITRA Successfully Treats Erectile Dysfunction (ED) in Men with Dyslipidemia, Including High Cholesterol
9. CSL Behring Study in Animal Models Shows Feasibility of Developing a Half-Life Extended Recombinant FVIIa that Retains Biologic Activity
10. Study Shows That Low-Molecular Weight Heparin (LMWH) was Associated with Reduced Hospital Costs of Venous Thromboembolism (VTE) Treatment Compared with Unfractionated Heparin (UFH)
11. Celator(R) Pharmaceuticals Reports CPX-351 Shows Anti-Cancer Activity in Leukemia Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... HAMBURG, Germany , Aug. 21, 2014  IBM (NYSE: ... Deutsches Elektronen-Synchrotron ( DESY ), a leading national research ... up management and storage of massive volumes of x-ray ... architecture based on IBM software defined technology can handle ... peak performance and help scientists worldwide gain faster insights ...
(Date:8/21/2014)... -- Zacks.com announces the list of stocks featured in the Analyst ... latest news and events impacting stocks and the financial markets. ... HPQ - Free Report ), IBM (NYSE: IBM - ... Free Report ), GlaxoSmithKline plc (NYSE: GSK - Free ... Free Report ). Today, Zacks is promoting its ...
(Date:8/21/2014)... Aug. 21, 2014  Henry Schein, Inc. (NASDAQ: ... and services to office-based dental, animal health and medical practitioners, ... conferences in September: , September 4, 2014 – ... , NY at 12:50 p.m. ET , September 8, 2014 ... New York , NY at 1:25 p.m. ET ...
Breaking Medicine Technology:DESY and IBM Develop Big Data Architecture for Science 2DESY and IBM Develop Big Data Architecture for Science 3The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 2The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 3The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 4The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 5The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 6The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 7The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 8The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 9The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 10The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 11Henry Schein To Present At Two Investor Conferences In September 2
... InCode BioPharmaceutics, Inc.,an emerging biopharmaceutical company, today ... their lead drug candidate rC3-1 for,the treatment ... nocturnal,hemoglobinuria (PNH). The complete results will be ... Basel, Switzerland, September 28,2008., The only ...
... a leading innovator,of physiological monitoring solutions for more ... with its breakthrough technology to measure,regional oxygen saturation. ... continuous monitoring of the regional blood oxygenation,in the ... and outcomes from an ongoing clinical study at ...
Cached Medicine Technology:InCode BioPharmaceutics, Inc. Announces Key Data Supporting New Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) 2Nonin Medical Inc. Announces Entry Into the Cerebral Oximeter Market 2
(Date:8/21/2014)... mothers are less likely than white moms to breast-feed ... in neighborhoods with many black residents do less to ... residents, a U.S. government study finds. Key practices ... centers where the black population is higher than average, ... Prevention reported Thursday. These practices include efforts to ...
(Date:8/21/2014)... THURSDAY, Aug. 21, 2014 (HealthDay News) -- Among seniors, ... suggests. The study involved more than 2,500 people, aged ... the study and again two, six and eight years later. ... in the person,s risk of death during the study period, ... and effect, researchers led by Sharon Christ of Purdue University ...
(Date:8/21/2014)... York, New York (PRWEB) August 21, 2014 ... filed against C.R. Bard, Inc. continue to move ... U.S. District Court, Southern District of West Virginia, ... Order issued on August 14th, the Court has ... evidence that requires special handling, division, storage and ...
(Date:8/21/2014)... to focus on her body in terms of how ... as a complete human being with thoughts and feelings. ... the media, how does it affect individual romantic relationships? ... , a SAGE journal, finds that more objectification of ... of sexual pressure and coercion., Researchers Laura R. Ramsey ...
(Date:8/21/2014)... FL (PRWEB) August 21, 2014 The ... published today in The Journal of the American Medical ... more invasive cancers and reduces unnecessary recalls. Memorial Healthcare ... in the study. , “This study confirms what we ... invasive, harmful cancers we want to find and, at ...
Breaking Medicine News(10 mins):Health News:Racial Disparities in Breast-Feeding May Start With Hospitals, Study Suggests 2Health News:Failing Vision Tied to Shorter Lifespans for Seniors 2Health News:Transvaginal Mesh Lawsuits Move Forward in Federal C.R. Bard Litigation with Issuance of New Pretrial Order, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuits Move Forward in Federal C.R. Bard Litigation with Issuance of New Pretrial Order, Bernstein Liebhard LLP Reports 3Health News:Objectification in romantic relationships related to sexual pressure and coercion 2Health News:Dr. Mary Hayes: Study Shows 3D Mammography Finds More Invasive Cancers While Reducing Unnecessary Recalls 2
... protein involved in Huntingtons disease take place earlier in ... College of Medicine in Houston in a report that ... , This research provides evidence of toxicity by huntingtin ... disease process, said Dr. Juan Botas, associate professor of ...
... As Americans increasingly seek a quick fix to physical ... crossfire of a debate about the potential benefits and ... A panel discussion entitled, The Uses of Medications in ... led by internationally renowned psychoanalyst Glen O. Gabbard, M.D., ...
... Department of Energy,s Brookhaven National Laboratory have found new ... while others don,t. Examining how the human brain responds ... various stages of fullness, the scientists have identified brain ... target these circuits may prove useful in controlling chronic ...
... Metabothin B56 with Ephedra Extract Released Just in Time for the Holiday ... ... CITY, Jan. 9 The average American gains 50%,of his yearly weight ... Americans that are already overweight., Metabothin ( http://www.metabothin.net ), the herbal ...
... can reduce healthcare costs by aiding in senior health and ... ... DSS Research, a,leader in market research for the health insurance industry, ... (SrHRA(TM)) for the 65 and over population. SrHRA provides,proven health risk stratification ...
... Bangladesh, Kenya, Tanzania and ... ... announced that it has,entered into four new technology transfers with local ... therapy are needed. These companies are Regal,Pharmaceuticals in Kenya, CAPS Holdings ...
Cached Medicine News:Health News:Uses of medications in psychoanalysis 2Health News:Overweight people may not know when they've had enough 2Health News:Overweight people may not know when they've had enough 3Health News:Metabothin B56 with Ephedra Extract Now Available 2Health News:DSS Research Announces Senior Health Risk Assessment Tool 2Health News:Roche Engages in Four Additional AIDS Technology Transfers to Strengthen Local Manufacturing in World's Poorest Countries 2Health News:Roche Engages in Four Additional AIDS Technology Transfers to Strengthen Local Manufacturing in World's Poorest Countries 3Health News:Roche Engages in Four Additional AIDS Technology Transfers to Strengthen Local Manufacturing in World's Poorest Countries 4
BioSoft alcohol gel hand antiseptic with soothing moisturizers is a fast-acting, broad-spectrum antimicrobial solution. BioSoft alcohol gel hand antiseptic applies easily, requires no rinsing and dri...
... Scrub Care povidone-iodine (PVP-I) antimicrobial solutions ... control in all hospital and health-care settings. ... gel have a broad spectrum of activity, ... bacteria that may cause infection. The new ...
... hand sanitizers like Aplicare No Rinse Isopropyl ... as the recommended product for hand disinfection ... Guidelines for hand hygiene., According to the ... be prevented with better infection control programs. ...
This is long known for its purity and mildness, Castile Soap is also an effective cleaning agent that is used in a variety of applications. It rinses clean while leaving the skin soft and healthy....
Medicine Products: